|
Ortho Biotech Products, L.P. is a leading biopharmaceutical company that provides innovative products and services designed to help enhance the lives of individuals with serious chronic illnesses. We market a prescription medication for chemotherapy-related anemia in patients with most types of cancer, for kidney disease patients with anemia who are not on dialysis, for anemia induced by AZT-containing regimens in HIV patients, and for patients undergoing elective, non-cardiac, non-vascular surgery who are anemic. More than two million patients in the United States alone have been treated with our products.
 Amgen is a leading human therapeutics company in the biotechnology industry. For 25 years, the company has tapped the power of scientific discovery and innovation to dramatically improve people’s lives.
Amgen pioneered the development of novel products based on advances in recombinant DNA and molecular biology and launched the biotechnology industry’s first blockbuster medicines. Today, as a Fortune 500 company serving millions of patients, Amgen continues to be an entrepreneurial, science-driven enterprise dedicated to helping people fight serious illness.
 Millennium has a major commitment to the discovery and development of new treatments for cancer, with a sizeable group focused on this area, including cancer biologists, world-leading experts in the field of genomics-based oncology and clinical oncology researchers. Our overall strategy in oncology is to develop novel treatments based on a thorough understanding of the molecular pathways that underlie different forms of cancer, and of the most appropriate points for therapeutic intervention within these pathways.
 In the first quarter of 2008, Eisai, Inc. purchased MGI Pharma. Eisai Inc. (pronounced â-zî) is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with sales of approximately $2.6 billion in fiscal year 2006 (year ending March 31, 2007).
Headquartered in Woodcliff Lake, New Jersey, we are dedicated to a tradition of genuine concern for people and are driven by the desire to meet the diverse health care needs of patients and their families and caregivers. We are an agile, entrepreneurial organization managed by experienced leadership, backed by the strength, stability and historical successes of Eisai Co., Ltd.., which has a strong and lasting commitment to the U.S. market.
|
Because hours are critical, Oncology Supply has made it a priority to respond to you with a spectrum of practice-building products and services. As one of the largest oncology distributors, Oncology Supply delivers over 1,800 chemotherapy and medical surgical products anywhere in the United States for next-day delivery. We offer a nationwide oncology network to help you optimize buying power and information. We also offer inventory management systems that order and capture lost revenue.
 Lilly is a pioneer in chemotherapy drugs, having introduced vincristine and vinblastine in the 1960s. These anticancer drugs, known as vinca alkaloids, were derived from the rosy periwinkle plant. In 1996, Lilly leveraged this expertise with the introduction of GEMZAR® (gemcitabine HCl for injection) for the treatment of non-small cell lung cancer, pancreatic cancer, and metastatic breast cancer.
ALIMTA as a single-agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after prior chemotherapy. The effectiveness of ALIMTA in second-line NSCLC was based on the surrogate endpoint, response rate. There are no controlled trials demonstrating a clinical benefit, such as a favorable survival effect or improvement of disease-related symptoms.
ALIMTA in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma (MPM) whose disease is unresectable or who are otherwise not candidates for curative surgery.
Other new chemotherapy drugs are now moving through the Lilly pipeline.
 Oncology Pharmaceutical Services offers community-based oncology practices a range of services designed to increase practice success – especially in today’s turbulent reimbursement environment.
The oncology drug management process is complex, and minor inefficiencies can significantly impact both quality and practice performance. Our programs and services help the community-based oncology practice optimize their drug management processes. These time-tested programs and services reflect oncology pharmacy best practices and are tailored to fit the needs of each specific practice.
|
